Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho

Hdl Handle:
http://hdl.handle.net/10144/255397
Title:
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho
Authors:
Jouquet, Guillaume; Bygrave, Helen; Kranzer, Katharina; Ford, Nathan; Gadot, Laurent; Lee, Janice; Hilderbrand, Katherine; Goemaere, Eric; Vlahakis, Natalie; Trivino, Laura; Makakole, Lipontso; Cleary, Susan
Journal:
Journal of Acquired Immune Deficiency Syndromes (JAIDS)
Abstract:
Latest World Health Organization guidelines recommend shifting away from Stavudine (d4T)-based regimens due to severe side effects. However, widespread replacement of d4T by Tenofovir (TDF) or Zidovudine (AZT) is hampered by cost concerns.
Affiliation:
Medecins Sans Frontieres, Morija, Lesotho; Department of Infectious and Tropical Diseases, Clinical Research Unit, London School of Hygiene and Tropical Medicine, UK; Medecins Sans Frontieres, Cape Town, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Medecins Sans Frontieres, Geneva, Switzerland; Scott Hospital, Morija, Lesotho; Health Economics Unit, University of Cape Town, South Africa
Publisher:
Lippincott Williams & Wilkins
Issue Date:
1-Nov-2011
URI:
http://hdl.handle.net/10144/255397
DOI:
10.1097/QAI.0b013e31822a9f8d
PubMed ID:
21765366
Additional Links:
http://journals.lww.com/jaids/Fulltext/2011/11010/Cost_and_Cost_Effectiveness_of_Switching_From_d4T.21.aspx#
Type:
Article
Language:
en
Description:
Article approval pending
ISSN:
1944-7884
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorJouquet, Guillaumeen
dc.contributor.authorBygrave, Helenen
dc.contributor.authorKranzer, Katharinaen
dc.contributor.authorFord, Nathanen
dc.contributor.authorGadot, Laurenten
dc.contributor.authorLee, Janiceen
dc.contributor.authorHilderbrand, Katherineen
dc.contributor.authorGoemaere, Ericen
dc.contributor.authorVlahakis, Natalieen
dc.contributor.authorTrivino, Lauraen
dc.contributor.authorMakakole, Lipontsoen
dc.contributor.authorCleary, Susanen
dc.date.accessioned2012-12-11T23:32:18Z-
dc.date.available2012-12-11T23:32:18Z-
dc.date.issued2011-11-01-
dc.identifier.citationJAIDS 2011; 58(3):e68-e74en
dc.identifier.issn1944-7884-
dc.identifier.pmid21765366-
dc.identifier.doi10.1097/QAI.0b013e31822a9f8d-
dc.identifier.urihttp://hdl.handle.net/10144/255397-
dc.descriptionArticle approval pending-
dc.description.abstractLatest World Health Organization guidelines recommend shifting away from Stavudine (d4T)-based regimens due to severe side effects. However, widespread replacement of d4T by Tenofovir (TDF) or Zidovudine (AZT) is hampered by cost concerns.en
dc.language.isoenen
dc.publisherLippincott Williams & Wilkinsen
dc.relation.urlhttp://journals.lww.com/jaids/Fulltext/2011/11010/Cost_and_Cost_Effectiveness_of_Switching_From_d4T.21.aspx#en
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en
dc.subject.meshAdenineen
dc.subject.meshAdulten
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntiretroviral Therapy, Highly Activeen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshDeveloping Countriesen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHealth Care Costsen
dc.subject.meshHumansen
dc.subject.meshLesothoen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPhosphonic Acidsen
dc.subject.meshPregnancyen
dc.subject.meshRural Populationen
dc.subject.meshStavudineen
dc.subject.meshZidovudineen
dc.titleCost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesothoen
dc.typeArticleen
dc.contributor.departmentMedecins Sans Frontieres, Morija, Lesotho; Department of Infectious and Tropical Diseases, Clinical Research Unit, London School of Hygiene and Tropical Medicine, UK; Medecins Sans Frontieres, Cape Town, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Medecins Sans Frontieres, Geneva, Switzerland; Scott Hospital, Morija, Lesotho; Health Economics Unit, University of Cape Town, South Africaen
dc.identifier.journalJournal of Acquired Immune Deficiency Syndromes (JAIDS)en

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.